These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 1827591)

  • 1. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
    Rouy D; Grailhe P; Nigon F; Chapman J; Anglés-Cano E
    Arterioscler Thromb; 1991; 11(3):629-38. PubMed ID: 1827591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
    Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
    Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
    Angles-Cano E; Rouy D; Lijnen HR
    Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study.
    Rouy D; Laplaud PM; Saboureau M; Anglés-Cano E
    Arterioscler Thromb; 1992 Feb; 12(2):146-54. PubMed ID: 1531929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a), fibrin binding, and plasminogen activation.
    Loscalzo J; Weinfeld M; Fless GM; Scanu AM
    Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a).
    Soulat T; Loyau S; Baudouin V; Durlach V; Gillery P; Garnotel R; Loirat C; Anglés-Cano E
    Thromb Haemost; 1999 Jul; 82(1):121-7. PubMed ID: 10456465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein (a) regulates plasmin generation and inhibition.
    Edelberg J; Pizzo SV
    Chem Phys Lipids; 1994 Jan; 67-68():363-8. PubMed ID: 8187236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of fibrinolysis by lipoprotein(a).
    Anglés-Cano E; de la Peña Díaz A; Loyau S
    Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin.
    Harpel PC; Gordon BR; Parker TS
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3847-51. PubMed ID: 2524834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of inhibition by lipoprotein (a) inhibition of tPA induced thrombolysis in a patient's plasma milieu.
    Lu H; Bruckert J; Soria J; Li H; de Gennes JL; Legrand A; Peynet J; Soria C
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):513-6. PubMed ID: 1966796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator.
    Liu JN; Harpel PC; Pannell R; Gurewich V
    Biochemistry; 1993 Sep; 32(37):9694-700. PubMed ID: 8373773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin.
    Liu J; Harpel PC; Gurewich V
    Biochemistry; 1994 Mar; 33(9):2554-60. PubMed ID: 8117716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
    Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
    Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
    Hancock MA; Boffa MB; Marcovina SM; Nesheim ME; Koschinsky ML
    J Biol Chem; 2003 Jun; 278(26):23260-9. PubMed ID: 12697748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
    Suenson E; Thorsen S
    Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein Lp(a) and atherothrombotic disease.
    de la Peña-Díaz A; Izaguirre-Avila R; Anglés-Cano E
    Arch Med Res; 2000; 31(4):353-9. PubMed ID: 11068075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inter-relation of fibrin, lipoprotein(a) and plasminogen in human atherosclerotic lesions.
    Smith EB; Crosbie L; Cochran S
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):495-8. PubMed ID: 2151935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces.
    Anglés-Cano E
    Chem Phys Lipids; 1994 Jan; 67-68():353-62. PubMed ID: 8187235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.